COMP <GO>
ASST vs JPM // FREE CASH FLOW YIELD
Strive Inc. (NASDAQ) VS. JPMorgan Chase & Co. (NYSE) • 15-METRIC TALLY: ASST 5
— JPM 9
▲ FREE CASH FLOW YIELD LEADER: ASST
LAST: $22.20 (-10.88%) • MKT CAP: $3.17B
fcf-yield
2.21%
LAST: $337.04 (-1.90%) • MKT CAP: $895.92B
fcf-yield
-18.14%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASST VS. JPM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ASST | JPM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.80% | 17.37% | +1.43 | ASST | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.7x | 9.7x | +10.03 | JPM | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 2.21% | -18.14% | +20.35 | ASST | /fcf-yield <GO> |
| Operating Margin | 13.90% | 42.07% | -28.17 | JPM | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 32.63% | -21.73 | JPM | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 13.53% | +166.47 | ASST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.96% | -1.96 | JPM | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 0.37 | +25.63 | ASST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 2/9 | +7.00 | ASST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 4.84% | +1.66 | JPM | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.7 | 49.0 | -12.34 | JPM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 1.00 | -0.11 | JPM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.6x | 13.6x | +14.03 | JPM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.17B | $895.92B | -$892.74B | JPM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ASST REV | JPM REV | ASST GROSS % | JPM GROSS % | ASST FCF | JPM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $182.45B | — | — | $0 | -$147.78B |
| FY 2024 | $3.6M | $177.56B | 44.0% | — | -$21.6M | -$42.01B |
| FY 2023 | $277.0K | $158.10B | 44.0% | — | -$3.8M | $12.97B |
| FY 2022 | — | $128.69B | — | — | — | $107.12B |
| FY 2021 | — | $121.65B | — | — | — | $78.08B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASST // BETA 0.89
JPM // BETA 1.00